- Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. results from a phase Ib clinical trial. Correale, P., Campoccia, G., Tsang, K.Y., Micheli, L., Cusi, M.G., Sabatino, M., Bruni, G., Sestini, S., Petrioli, R., Pozzessere, D., Marsili, S., Fanetti, G., Giorgi, G., Francini, G. Eur. J. Cancer (2001)